- Country: Uruguay
- Summary: Item 1: up to 9000 Tablets of Leflunomide 20 Mg, Presentation: Blister X 30 Tablets, Item 2: up to 4000 Tablets of Alendronate 70 Mg, Presentation: Blister
- UYT Ref No: 94964472
- Deadline: 11 Jan 2024
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: Refer Document
- Notice Type: Tender
- Document Ref. No.: Compra Directa 59/2024
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- ITEM 1: UP TO 9000 TABLETS OF LEFLUNOMIDE 20 MG, PRESENTATION: BLISTER X 30 TABLETS, ITEM 2: UP TO 4000 TABLETS OF ALENDRONATE 70 MG, PRESENTATION: BLISTER LISTER 20 TABLETS. see attached fileMandatory documentation to be submitted
- Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINItem 1: up to 9000 Tablets of Leflunomide 20 Mg, Presentation: Blister X 30 Tablets, Item 2: up to 4000 Tablets of Alendronate 70 Mg, Presentation: Blister - Uruguay Tender
The STATE HEALTH SERVICES ADMINISTRATION | NATIONAL INSTITUTE OF RHEUMATOLOGY PROF.DR. MOSES MIZRACHI, a Government sector organization in Uruguay, has announced a new tender for Item 1: up to 9000 Tablets of Leflunomide 20 Mg, Presentation: Blister X 30 Tablets, Item 2: up to 4000 Tablets of Alendronate 70 Mg, Presentation: Blister. This tender is published on UruguayTenders under UYT Ref No: 94964472 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2024-01-11.
The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
